Akero Therapeutics Inc (AKRO)
19.94
-0.80
(-3.84%)
USD |
NASDAQ |
May 17, 16:00
19.94
0.00 (0.00%)
After-Hours: 20:00
Akero Therapeutics SG&A Expense (Quarterly): 9.304M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 9.304M |
December 31, 2023 | 8.481M |
September 30, 2023 | 7.981M |
June 30, 2023 | 7.644M |
March 31, 2023 | 6.966M |
December 31, 2022 | 7.10M |
September 30, 2022 | 11.00M |
June 30, 2022 | 6.231M |
March 31, 2022 | 5.537M |
December 31, 2021 | 4.728M |
September 30, 2021 | 4.883M |
June 30, 2021 | 4.99M |
March 31, 2021 | 4.526M |
Date | Value |
---|---|
December 31, 2020 | 4.074M |
September 30, 2020 | 4.159M |
June 30, 2020 | 3.417M |
March 31, 2020 | 3.588M |
December 31, 2019 | 3.083M |
September 30, 2019 | 2.424M |
June 30, 2019 | 1.649M |
March 31, 2019 | 1.449M |
December 31, 2018 | 0.985M |
September 30, 2018 | 0.474M |
June 30, 2018 | 0.242M |
March 31, 2018 | 0.195M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.649M
Minimum
Jun 2019
11.00M
Maximum
Sep 2022
5.588M
Average
4.936M
Median
SG&A Expense (Quarterly) Benchmarks
89bio Inc | 9.849M |
Madrigal Pharmaceuticals Inc | 80.80M |
Viking Therapeutics Inc | 9.97M |
Ionis Pharmaceuticals Inc | 52.64M |
Galectin Therapeutics Inc | 1.594M |